273 related articles for article (PubMed ID: 10493531)
21. Measurement of ThioTEPA and Its Metabolite TEPA in Plasma and Cerebrospinal Fluid by Turbulent Flow Chromatography-Tandem Mass Spectrometry.
Schofield RC; Scordo M; Shah G; Carlow DC
Methods Mol Biol; 2024; 2737():423-433. PubMed ID: 38036843
[TBL] [Abstract][Full Text] [Related]
22. Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency.
Ekhart C; Kerst JM; Rodenhuis S; Beijnen JH; Huitema AD
Cancer Chemother Pharmacol; 2009 Jan; 63(2):375-9. PubMed ID: 18431571
[TBL] [Abstract][Full Text] [Related]
23. Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of N,N',N''-triethylenethiophosphoramide.
Teicher BA; Waxman DJ; Holden SA; Wang YY; Clarke L; Alvarez Sotomayor E; Jones SM; Frei E
Cancer Res; 1989 Sep; 49(18):4996-5001. PubMed ID: 2504483
[TBL] [Abstract][Full Text] [Related]
24. High-dose N,N',N"-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies.
Wolff SN; Herzig RH; Fay JW; LeMaistre CF; Brown RA; Frei-Lahr D; Stranjord S; Giannone L; Coccia P; Weick JL
Semin Oncol; 1990 Feb; 17(1 Suppl 3):2-6. PubMed ID: 2106165
[TBL] [Abstract][Full Text] [Related]
25. Quantification of N, N' N"-triethylenethiophosphoramide, N, N"-triethylenephosphoramide, cyclophosphamide, and 4-hydroxy-cyclophosphamide in microvolume human plasma to support neonatal and pediatric drug studies.
Huang L; Winger BA; Cheah V; Gingrich D; Marzan F; Lu Y; Cooper JC; Aweeka F; Long-Boyle J
J Chromatogr Open; 2022 Nov; 2():. PubMed ID: 35875822
[TBL] [Abstract][Full Text] [Related]
26. Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy.
de Jonge ME; Mathôt RA; Dalesio O; Huitema AD; Rodenhuis S; Beijnen JH
Bone Marrow Transplant; 2002 Nov; 30(9):593-7. PubMed ID: 12407434
[TBL] [Abstract][Full Text] [Related]
27. Liquid chromatographic-mass spectrometric determination of the novel, recently identified thioTEPA metabolite, thioTEPA-mercapturate, in urine.
van Maanen MJ; Beijnen JH
J Chromatogr B Biomed Sci Appl; 1999 Sep; 732(1):73-9. PubMed ID: 10517224
[TBL] [Abstract][Full Text] [Related]
28. Influence of co-medicated drugs on the biotransformation of thioTEPA to TEPA and thioTEPA-mercapturate.
van Maanen MJ; Huitema AD; Beijen JH
Anticancer Res; 2000; 20(3A):1711-6. PubMed ID: 10928097
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of intraventricular and intravenous N,N',N''-triethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans.
Strong JM; Collins JM; Lester C; Poplack DG
Cancer Res; 1986 Dec; 46(12 Pt 1):6101-4. PubMed ID: 3096555
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S
Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935
[TBL] [Abstract][Full Text] [Related]
31. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.
Huitema AD; Spaander M; Mathĵt RA; Tibben MM; Holtkamp MJ; Beijnen JH; Rodenhuis S
Ann Oncol; 2002 Mar; 13(3):374-84. PubMed ID: 11996467
[TBL] [Abstract][Full Text] [Related]
32. Alkylation of DNA with aziridine produced during the hydrolysis of N,N',N''-triethylenethiophosphoramide.
Musser SM; Pan SS; Egorin MJ; Kyle DJ; Callery PS
Chem Res Toxicol; 1992; 5(1):95-9. PubMed ID: 1374653
[TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
de Jonge ME; Huitema AD; van Dam SM; Rodenhuis S; Beijnen JH
Ther Drug Monit; 2005 Dec; 27(6):756-65. PubMed ID: 16306851
[TBL] [Abstract][Full Text] [Related]
34. Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.
Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
Br J Clin Pharmacol; 2009 Jan; 67(1):50-60. PubMed ID: 19076156
[TBL] [Abstract][Full Text] [Related]
35. Metabolism and alkylating activity of thio-TEPA in rat liver slice incubation.
Hagen B; Dale O; Neverdal G; Azri S; Nilsen OG
Cancer Chemother Pharmacol; 1991; 28(6):441-7. PubMed ID: 1718615
[TBL] [Abstract][Full Text] [Related]
36. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
37. Isolation and structure elucidation of urinary metabolites of mitoxantrone.
Blanz J; Mewes K; Ehninger G; Proksch B; Greger B; Waidelich D; Zeller KP
Cancer Res; 1991 Jul; 51(13):3427-33. PubMed ID: 2054783
[TBL] [Abstract][Full Text] [Related]
38. Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.
Tiersten A; Wo J; Jacobson C; Weitzman A; Horwich T; Hesdorffer C; Savage D; Troxel A
Breast; 2004 Aug; 13(4):341-6. PubMed ID: 15325671
[TBL] [Abstract][Full Text] [Related]
39. Biotransformation of 2,3,3,3-tetrafluoropropene (HFO-1234yf).
Schuster P; Bertermann R; Snow TA; Han X; Rusch GM; Jepson GW; Dekant W
Toxicol Appl Pharmacol; 2008 Dec; 233(2):323-32. PubMed ID: 18817801
[TBL] [Abstract][Full Text] [Related]
40. Characterization of nonexchangeable radioactivity in L1210 cells incubated with [14C]thiotepa: labeling of phosphatidylethanolamine.
Egorin MJ; Snyder SW
Cancer Res; 1990 Jul; 50(13):4044-9. PubMed ID: 2112983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
